Robert M. Janosky
Corporate Officer/Principal bei SATSUMA PHARMACEUTICALS, INC.
Aktive Positionen von Robert M. Janosky
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05.03.2020 | - |
Karriereverlauf von Robert M. Janosky
Ehemalige bekannte Positionen von Robert M. Janosky
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DURECT CORPORATION | Corporate Officer/Principal | 01.01.2016 | 01.03.2020 |
Ausbildung von Robert M. Janosky
| University of Vermont | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Börse
- Insiders
- Robert M. Janosky
- Erfahrung
